<?xml version="1.0"?>
<?xml-stylesheet type="text/xsl" href="billres.xsl"?>
<!DOCTYPE bill PUBLIC "-//US Congress//DTDs/bill.dtd//EN" "bill.dtd">
<bill bill-stage="Introduced-in-House" dms-id="H4B48AB0BB625406B91F212564DA5E209" public-private="public" key="H" bill-type="olc"><metadata xmlns:dc="http://purl.org/dc/elements/1.1/">
<dublinCore>
<dc:title>117 HR 6988 IH: Drug Manufacturing Innovation Act of 2022</dc:title>
<dc:publisher>U.S. House of Representatives</dc:publisher>
<dc:date>2022-03-08</dc:date>
<dc:format>text/xml</dc:format>
<dc:language>EN</dc:language>
<dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
</dublinCore>
</metadata>
<form>
<distribution-code display="yes">I</distribution-code><congress display="yes">117th CONGRESS</congress><session display="yes">2d Session</session><legis-num display="yes">H. R. 6988</legis-num><current-chamber>IN THE HOUSE OF REPRESENTATIVES</current-chamber><action display="yes"><action-date date="20220308">March 8, 2022</action-date><action-desc><sponsor name-id="L000593">Mr. Levin of California</sponsor> (for himself and <cosponsor name-id="J000302">Mr. Joyce of Pennsylvania</cosponsor>) introduced the following bill; which was referred to the <committee-name committee-id="HIF00">Committee on Energy and Commerce</committee-name></action-desc></action><legis-type>A BILL</legis-type><official-title display="yes">To amend the Federal Food, Drug, and Cosmetic Act to authorize a program to support the adoption of, and improve the development of, innovative approaches to pharmaceutical product design and manufacturing, and for other purposes.</official-title></form><legis-body id="H13A77687218443DA95B5DF45D036A258" style="OLC"><section id="H600483BB3D1E4379B78D62845FB38ACE" section-type="section-one"><enum>1.</enum><header>Short title</header><text display-inline="no-display-inline">This Act may be cited as the <quote><short-title>Drug Manufacturing Innovation Act of 2022</short-title></quote>.</text></section><section id="H035A6215875D4D54B3EA61D39606BE76"><enum>2.</enum><header>Emerging technology program</header><text display-inline="no-display-inline">Chapter V of the Federal Food, Drug, and Cosmetic Act (<external-xref legal-doc="usc" parsable-cite="usc/21/201">21 U.S.C. 201 et seq.</external-xref>) is amended by inserting after section 566 of such Act (<external-xref legal-doc="usc" parsable-cite="usc/21/360bbb-5">21 U.S.C. 360bbb–5</external-xref>) the following:</text><quoted-block style="OLC" id="H08C34D130A5E45D3B4B080034094856B" display-inline="no-display-inline"><section id="H497D357C8BA54625B6CB8E201DEDEDB5"><enum>566A.</enum><header>Emerging technology program</header><subsection id="HAE92FB1F40B24BBE841764BA1C5ABBD0"><enum>(a)</enum><header>Program establishment</header><paragraph id="H6FE78ED14F0E41CAA80FB1BBF69EC107"><enum>(1)</enum><header>In general</header><text>The Secretary shall establish a program to support the adoption of, and improve the development of, innovative approaches to pharmaceutical product design and manufacturing.</text></paragraph><paragraph id="HC090A125D841431A9E881057F977303D"><enum>(2)</enum><header>Actions</header><text>In carrying out the program under paragraph (1), the Secretary may—</text><subparagraph id="HC5EC604CB7B24B9E88D29AEE0A45DBDB"><enum>(A)</enum><text>facilitate and increase communication between public and private entities, consortia, and individuals with respect to innovative pharmaceutical product design and manufacturing;</text></subparagraph><subparagraph id="H0205549E97984ACA9DE0F62D5F3172AD"><enum>(B)</enum><text>solicit information regarding, and conduct or support research on, innovative approaches to pharmaceutical product design and manufacturing;</text></subparagraph><subparagraph id="H4BE87A160F4A4A3784161405ABBD6A03"><enum>(C)</enum><text>convene meetings with representatives of industry, academia, other Federal agencies, international agencies, and other interested persons, as appropriate;</text></subparagraph><subparagraph id="HDE39F3AD9EAD4471960703186FB2D13B"><enum>(D)</enum><text>convene working groups to support pharmaceutical product design and manufacturing research and development;</text></subparagraph><subparagraph id="HA919108D023A405186D1A65702933B23"><enum>(E)</enum><text>support education and training for regulatory staff and scientists related to innovative approaches to pharmaceutical product design and manufacturing;</text></subparagraph><subparagraph id="H1347AE379127433A9E0C47346765DD41"><enum>(F)</enum><text>conduct research and testing to develop or validate innovative approaches to pharmaceutical product design and manufacturing; </text></subparagraph><subparagraph id="H389211258B884879957D7FE7B91297C8"><enum>(G)</enum><text>advance regulatory science related to the development and review of innovative approaches to pharmaceutical product design and manufacturing; </text></subparagraph><subparagraph id="HF90767FE91E64FE4B5826174E96B6A56"><enum>(H)</enum><text>convene working groups to support the harmonization of international regulatory requirements related to innovative approaches to pharmaceutical product design and manufacturing; and</text></subparagraph><subparagraph id="HAF333FA509704BFA99A9FC92F2B6AB01"><enum>(I)</enum><text>award grants or contracts to carry out or support the program under paragraph (1).</text></subparagraph></paragraph><paragraph id="H1506A3E7F2BA4744AC7510BF47CB743B"><enum>(3)</enum><header>Grants and contracts</header><text>To seek a grant or contract under this section, an entity shall submit an application—</text><subparagraph id="H063B8B7388A54F04AEB2FAFA00DBEE9A"><enum>(A)</enum><text>in such form and manner as the Secretary may require; and</text></subparagraph><subparagraph id="HD6D302A65265426E90ACD54C1769DBC2"><enum>(B)</enum><text>containing such information as the Secretary may require, including a description of—</text><clause id="H50E84760C7B74005BA3850B14DEBA4D2"><enum>(i)</enum><text>how the entity will conduct the activities to be supported through the grant or contract; and</text></clause><clause id="H9B5A630B8B7E4B65BA992BDDA4781F6C"><enum>(ii)</enum><text>how such activities will further research and development related to, or adoption of, innovative approaches to pharmaceutical product design and manufacturing.</text></clause></subparagraph></paragraph></subsection><subsection id="HD5A0A9937832443B9D9FBE07546C76AB"><enum>(b)</enum><header>Guidance</header><text>The Secretary shall—</text><paragraph id="HF7EB2C1999054529A7662775A222D368"><enum>(1)</enum><text>issue or update guidance to help facilitate the adoption of, and advance the development of, innovative approaches to pharmaceutical product design and manufacturing; and</text></paragraph><paragraph id="HABAC3137DF5946A8A6F294C0AF49F9CB"><enum>(2)</enum><text>include in such guidance descriptions of—</text><subparagraph id="HD17CC319E7A246868CA3BD8BD339BF11"><enum>(A)</enum><text>any regulatory requirements related to the development or review of technologies related to innovative approaches to pharmaceutical product design and manufacturing, including regulatory requirements necessary for updates and improvements to such technologies after product approval; and</text></subparagraph><subparagraph id="H564A469BCB1345048046566301961B8C"><enum>(B)</enum><text>data required to demonstrate the identity, safety, purity, and potency of drugs manufactured using such technologies.</text></subparagraph></paragraph></subsection><subsection id="H2ED7F6C51D0E4A748818A04B17927692"><enum>(c)</enum><header>Report to Congress</header><text display-inline="yes-display-inline">Not later than 4 years after the date of enactment of this section, the Secretary shall submit to the Committee on Energy and Commerce of the House of Representatives and the Committee on Health, Education, Labor, and Pensions of the Senate a report containing—</text><paragraph id="H2B7D09F1EA814FB2B22DA45878F6DCFE"><enum>(1)</enum><text>an annual accounting of the allocation of funds made available to carry out this section; </text></paragraph><paragraph id="H7C34DD727C6F406BB5FDDF461B1D86A2"><enum>(2)</enum><text>the number of full-time equivalent staff dedicated to the program under subsection (a)(1);</text></paragraph><paragraph id="HFDC6994F24714101BDCA0C99DD1C292A"><enum>(3)</enum><text>the number of meetings held by the Food and Drug Administration, including meetings convened as part of a working group described in subparagraph (D) or (H) of paragraph (2) of subsection (a), and the topics of each such meeting; and</text></paragraph><paragraph id="H4FBAA7855D9A4574A1647D0A7B51AD1D"><enum>(4)</enum><text>the number of products approved or licensed, after the date of enactment of this section, using an innovative approach to pharmaceutical product design and manufacturing.</text></paragraph></subsection><subsection id="HDEB4991E64774D64AA24D4528FA9FDF2"><enum>(d)</enum><header>Authorization of appropriations</header><text>To carry out this section, there is authorized to be appropriated $20,000,000 for each fiscal year 2023 through 2027.</text></subsection></section><after-quoted-block>.</after-quoted-block></quoted-block></section></legis-body></bill> 

